Literature DB >> 2292364

Induction of differentiation of the human histiocytic lymphoma cell line U937 in the absence of vimentin expression.

M Taimi1, M T Château, J Marti, M Pacaud.   

Abstract

We have studied the expression of vimentin in the human histiocytic lymphoma cell line U937, induced to differentiate along the monocyte/macrophage pathway. Normal monocytes possess a network of vimentin intermediate filaments (IFs) at all stages of maturation. The undifferentiated U937 leukemia cells contain very low amounts of vimentin, but express a conspicuous IF network when exposed to phorbol myristate acetate. In parallel, they acquire functional properties typical of cells of the monocyte lineage. These concomitant variations suggest that vimentin IFs could play a role in the process of differentiation. However, we observed that all-trans-retinoic acid and 1,25-dihydroxyvitamin D3 confer monocyte-like properties upon U937 cells without inducing vimentin expression. We obtained increased phenotypic changes, yet in the absence of a vimentin network, by combining the effects of both inducers. These results show that vimentin expression is not crucial for the acquisition of some of the functions characteristic of the monocyte/macrophage lineage.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2292364     DOI: 10.1111/j.1432-0436.1990.tb00457.x

Source DB:  PubMed          Journal:  Differentiation        ISSN: 0301-4681            Impact factor:   3.880


  3 in total

1.  Effects of mesenchymal stem cell and fibroblast coating on immunogenic potential of prosthetic meshes in vitro.

Authors:  Yue Gao; David M Krpata; Cory N Criss; Lijia Liu; Natasza Posielski; Michael J Rosen; Yuri W Novitsky
Journal:  Surg Endosc       Date:  2014-06-28       Impact factor: 4.584

2.  The retinoic acid analog CBS-211A potentiates the 1 alpha,25-dihydroxyvitamin D3-induced differentiation of U937 cells.

Authors:  M Taimi; H Defacque; T Commes; J Favero; J Dornand; J Marti
Journal:  Agents Actions       Date:  1993-01

3.  Different vimentin expression in two clones derived from a human colocarcinoma cell line (LoVo) showing different sensitivity to doxorubicin.

Authors:  G Conforti; A M Codegoni; E Scanziani; E Dolfini; T Dasdia; M Calza; M Caniatti; M Broggini
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.